LUNG (Pulmonx) חוב כולל להון

The growth of Pulmonx Corporation (LUNG) relies on the popularity of Zephyr systems for emphysema therapy and insurance availability, as illustrated by this chart of the total debt-to-equity ratio at 1.66. Geopolitical tensions and sanctions limit sales in several countries, complicating transportation. Meanwhile, counterparty diversification and the establishment of backup electronics warehouses ensure an uninterrupted supply of pulmonology devices.

This metric determines the degree of financial leverage by comparing total liabilities to net asset value to assess bankruptcy risks and the cost of capital. An analysis of the total debt-to-equity ratio reveals the extent to which the implementation of digital platforms for precision surgical planning at Pulmonx Corporation (LUNG) is funded through borrowed funds or internal resources.